Phase 1 trial of SHR-A2102, a nectin-4–directed antibody drug conjugate (ADC), in advanced solid tumors. Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results